C-CAR031 is based on a novel GPC3-targeting CAR-T (AZD5851) designed by AstraZeneca using their transforming growth factor-beta receptor II
The agreement includes an upfront payment of US$15 million, regulatory and commercial milestones, and royalties
Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases
Astria will assume full cost and responsibility for the global development and commercialization of the licensed therapeutic program for all indications
Biocon will be responsible for obtaining regulatory approval for Liraglutide, and thereafter, for the manufacture and supply of the product in the Canadian market
The introduction of 'Definisse Core Filler' is a testament to the company's premium scientific-based innovation
Sun Pharma is granted rights for marketing Sovateltide in India under the brand name Tyvalzi (Sovateltide)
Patients Treated with ARIKAYCE plus macrolide-based background regimen had meaningfully larger improvements in QOL-B respiratory score
The facility has a potential for capacity expansion up to 2 billion tablets/capsules per year
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
